| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Fepixnebart | LY-3016859 | Phase 2 Clinical | Eli Lilly And Company | Diabetic Nephropathies; Diabetic Neuropathies; Low Back Pain; Osteoarthritis; Osteoarthritis, Knee | Details |